Literature DB >> 18783208

Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.

Neva Lazarova1, Sami S Zoghbi, Jinsoo Hong, Nicholas Seneca, Ed Tuan, Robert L Gladding, Jeih-San Liow, Andrew Taku, Robert B Innis, Victor W Pike.   

Abstract

[(11)C]Loperamide has been proposed for imaging P-glycoprotein (P-gp) function with positron emission tomography (PET), but its metabolism to [N-methyl-(11)C] N-desmethyl-loperamide ([(11)C]dLop; [(11)C]3) precludes quantification. We considered that [(11)C]3 might itself be a superior radiotracer for imaging brain P-gp function and therefore aimed to prepare [(11)C]3 and characterize its efficacy. An amide precursor (2) was synthesized and methylated with [(11)C]iodomethane to give [(11)C]3. After administration of [(11)C]3 to wild-type mice, brain radioactivity uptake was very low. In P-gp (mdr-1a(-/-)) knockout mice, brain uptake of radioactivity at 30 min increased about 3.5-fold by PET measures, and over 7-fold by ex vivo measures. In knockout mice, brain radioactivity was predominantly (90%) unchanged radiotracer. In monkey PET experiments, brain radioactivity uptake was also very low but after P-gp blockade increased more than 7-fold. [(11)C]3 is an effective new radiotracer for imaging brain P-gp function and, in favor of future successful quantification, appears free of extensive brain-penetrant radiometabolites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783208      PMCID: PMC2646255          DOI: 10.1021/jm800510m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

Review 1.  PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.

Authors:  Philip H Elsinga; N Harry Hendrikse; Joost Bart; Willem Vaalburg; Aren van Waarde
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY.

Authors:  Jeih-San Liow; Shuiyu Lu; Julie A McCarron; Jinsoo Hong; John L Musachio; Victor W Pike; Robert B Innis; Sami S Zoghbi
Journal:  Synapse       Date:  2007-02       Impact factor: 2.562

3.  A comparison of the brain uptake of N-(cyclopropyl[11C]methyl)norbuprenorphine ([11C]buprenorphine) and N-(cyclopropyl[11C]methyl)nordiprenorphine ([11C]diprenorphine) in baboon using PET.

Authors:  C Y Shiue; L Q Bai; R R Teng; C D Arnett; S L Dewey; A P Wolf; D W McPherson; J S Fowler; J Logan; M J Holland
Journal:  Int J Rad Appl Instrum B       Date:  1991

4.  Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi.

Authors:  Heather M Bigott; Julie L Prior; David R Piwnica-Worms; Michael J Welch
Journal:  Mol Imaging       Date:  2005 Jan-Mar       Impact factor: 4.488

5.  Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

Authors:  A H Dantzig; R L Shepard; K L Law; L Tabas; S Pratt; J S Gillespie; S N Binkley; M T Kuhfeld; J J Starling; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

6.  In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.

Authors:  S D Vecchio; A Ciarmiello; M I Potena; M V Carriero; C Mainolfi; G Botti; R Thomas; M Cerra; G D'Aiuto; T Tsuruo; M Salvatore
Journal:  Eur J Nucl Med       Date:  1997-02

7.  11C-GR103545, a radiotracer for imaging kappa-opioid receptors in vivo with PET: synthesis and evaluation in baboons.

Authors:  Peter S Talbot; Raj Narendran; Eduardo R Butelman; Yiyun Huang; Kim Ngo; Mark Slifstein; Diana Martinez; Marc Laruelle; Dah-Ren Hwang
Journal:  J Nucl Med       Date:  2005-03       Impact factor: 10.057

8.  P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

Authors:  A H Schinkel; E Wagenaar; C A Mol; L van Deemter
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET.

Authors:  P H Elsinga; E J Franssen; N H Hendrikse; L Fluks; A M Weemaes; W T van der Graaf; E G de Vries; G M Visser; W Vaalburg
Journal:  J Nucl Med       Date:  1996-09       Impact factor: 10.057

Review 10.  Loperamide. Survey of studies on mechanism of its antidiarrheal activity.

Authors:  F Awouters; A Megens; M Verlinden; J Schuurkes; C Niemegeers; P A Janssen
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

View more
  31 in total

1.  P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.

Authors:  William C Kreisl; Jeih-San Liow; Nobuyo Kimura; Nicholas Seneca; Sami S Zoghbi; Cheryl L Morse; Peter Herscovitch; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

Review 2.  Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.

Authors:  Wolfgang Löscher; Oliver Langer
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  Evaluation of [18F]MC225 as a PET radiotracer for measuring P-glycoprotein function at the blood-brain barrier in rats: Kinetics, metabolism, and selectivity.

Authors:  Heli Savolainen; Albert D Windhorst; Philip H Elsinga; Mariangela Cantore; Nicola A Colabufo; Antoon Tm Willemsen; Gert Luurtsema
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

4.  Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice.

Authors:  Nicholas Seneca; Sami S Zoghbi; H Umesha Shetty; Edward Tuan; Pavitra Kannan; Andrew Taku; Robert B Innis; Victor W Pike
Journal:  Nucl Med Biol       Date:  2010-04       Impact factor: 2.408

5.  Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.

Authors:  Florian Bauer; Claudia Kuntner; Jens P Bankstahl; Thomas Wanek; Marion Bankstahl; Johann Stanek; Severin Mairinger; Bernd Dörner; Wolfgang Löscher; Markus Müller; Thomas Erker; Oliver Langer
Journal:  Bioorg Med Chem       Date:  2010-06-22       Impact factor: 3.641

Review 6.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 7.  Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

Authors:  Stina Syvänen; Jonas Eriksson
Journal:  ACS Chem Neurosci       Date:  2012-12-04       Impact factor: 4.418

Review 8.  Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications.

Authors:  P Kannan; C John; S S Zoghbi; C Halldin; M M Gottesman; R B Innis; M D Hall
Journal:  Clin Pharmacol Ther       Date:  2009-07-22       Impact factor: 6.875

Review 9.  PET radiotracers: crossing the blood-brain barrier and surviving metabolism.

Authors:  Victor W Pike
Journal:  Trends Pharmacol Sci       Date:  2009-07-16       Impact factor: 14.819

10.  P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.

Authors:  Jeih-San Liow; William Kreisl; Sami S Zoghbi; Neva Lazarova; Nicholas Seneca; Robert L Gladding; Andrew Taku; Peter Herscovitch; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.